Delivery Order SPE2DB22D1017-SPE2DB25FYPRY
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,813.19 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat moderate-to-severe eczema, asthma, and...
- The Defense Logistics Agency awarded a $54,501.62 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 27, 2025, with ultimate completion by August 28, 2025. This firm fixed-price, competitively awarded contract—without set-aside designation—will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic...
- The Defense Logistics Agency awarded a $37,116.52 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, which is not set-aside and carries firm fixed pricing, is scheduled for ultimate completion by August 29, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location in the same city....
- The Defense Logistics Agency awarded a $11,417.33 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on August 19, 2025, with completion targeted for August 20, 2025. This firm fixed-price, competitively awarded delivery order was issued without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a prescription biologic medication primarily used to treat...
- The Defense Logistics Agency awarded a $17,094.60 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 29, 2025, with completion expected by September 2, 2025. This firm fixed price delivery order was competitively awarded without set-aside provisions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions including...
- The Defense Logistics Agency awarded a delivery order valued at $37,531.67 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price, competitively awarded contract (no set-aside used) is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat atopic dermatitis, eosinophilic esophagitis, and asthma,...
- The Defense Logistics Agency awarded a $68,986.58 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a firm fixed price transaction under an existing Indefinite Delivery Contract vehicle. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- The Defense Logistics Agency awarded a $21,976.95 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with a completion date of July 29, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, chronic rhinosinusitis with nasal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $10,591.02. This is a firm fixed price delivery order with no set-aside designation, awarded competitively to the prime contractor. The order is to be completed by August 6, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a...
- The Defense Logistics Agency awarded a delivery order valued at $103,490.97 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 29, 2025, with an ultimate completion date of July 30, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. Dupixent is a biologic...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FYPRYDelivery Order
The Defense Logistics Agency awarded a $7,247.34 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on September 2, 2025, with completion scheduled for September 3, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various allergic and inflammatory conditions, representing a critical pharmaceutical commodity within the Defense Logistics Agency's medical supply chain operations. This delivery order is executed under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen Drug Corp supplies an extensive portfolio of medications and medical supplies to support military healthcare systems worldwide, including the Defense Health Agency and U.S. Coast Guard. The company's competitive positioning in federal pharmaceutical procurement reflects its established capability to meet rigorous federal procurement standards and deliver specialized medical commodities efficiently to support defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.2k | 9/2/25 |